Live Breaking News & Updates on Endocrine metabolic

Stay informed with the latest breaking news from Endocrine metabolic on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Endocrine metabolic and stay connected to the pulse of your community

Move over, Humira, there's a new mega-blockbuster in town

There was a time not that long ago when Merck & Co. Inc.’s Keytruda (pembrolizumab), with its multiple cancer indications, was seen as the heir apparent to Humira’s title of the biggest blockbuster drug. Not anymore. That title now belongs to Novo Nordisk A/S’ semaglutide, approved as Ozempic in 2017 to treat diabetes and as Wegovy in 2021 to help with weight loss.

Novo-nordisk , Merck-co , Novo-nordiska-s , Semaglutide , Ozempic , Wegovy , Humira , Adalimumab , Keytruda , Merck-amp-co-inc- , Pembrolizumab , Abbvie-inc-

Vertex buying Alpine for $4.9B for phase III-ready IgAN asset

Vertex Pharmaceuticals Inc. is acquiring Alpine Immune Sciences Inc. for $4.9 billion in cash to gain Alpine’s lead product, phase III-ready povetacicept, which demonstrates best-in-class potential in patients with immunoglobulin A nephropathy (IgAN).

Reshma-kewalramani , Vertex-pharmaceuticals-inc , Alpine-immune-sciences-inc , Vertex-pharmaceuticals , Alpine-immune-sciences , Alpine-immune-sciences-inc- , Vertex-pharmaceuticals-inc- , Kidney-disease , Igan , Immunoglobulina-nephropathy , Immunoglobulin-a , Povetacicept

Australian scientists explore MERTK as a target against organ fibrosis

A small molecule could provide a new therapeutic approach against organ fibrosis. Using genome-wide association (GWA) assays, a group of researchers of the Westmead Institute for Medical Research in Sydney identified Mer tyrosine kinase (MERTK) as a candidate to study fibrosis and showed that its inhibition with the experimental compound reduced this condition in mouse models’ liver, kidneys and lungs.

Westmead , New-south-wales , Australia , Sydney , Mohammed-eslam , Westmead-institute-for-medical-research , Westmead-institute , Medical-research , Bioworld-science , Endocrine-metabolic , Fibrosis

Me-two drug? Viking mid-stage trial wins with GLP-1/GIP bid

The enticing prospect – and proven worth – of dually agonizing the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors gained more evidence in a big way from Viking Therapeutics Inc. with VK-2735 in a phase II weight loss study. Shares of San Diego-based Viking Therapeutics Inc. (NASDAQ:VKTX) closed Feb. 27 at $85.05, up $46.57, or 121%, as investors learned that the drug achieved the primary and all secondary endpoints in the phase II study called Venture, with significant body-weight drops at all doses compared to placebo.

Nasdaq , San-viking-therapeutics-inc , Therapeutics-inc , Viking-therapeutics , San-diego-based-viking-therapeutics , Viking-therapeutics-inc- , Vk-2735 , Glp-1 , Gip , Bioworld , Clinical

Immunoglobulin G antibody acts as a metabolic aging factor

Immunoglobulin G (IgG), an antibody that participates in the response to infection, could have a specific role in metabolism. During aging, it accumulates in certain tissues inducing metabolic dysfunction and fibrosis of fat tissue. This effect could be prevented through an intracellular receptor that contributes to the delivery of IgG. A team of researchers from Columbia University and Peking University (PKU) demonstrated that reducing excess IgG improved the metabolic health of aged mice and increased their life expectancy.

Peking , Beijing , China , Columbia-university , Peking-university , Bioworld-science , Igg , Fibrosis , Metabolic-dysfunction , Endocrine-metabolic , Drug-design

Synlogic pulls plug after peek at phenylketonuria phase III data

Synlogic Inc. jolted Wall Street with news that the firm is scrapping for futility Synpheny-3, its pivotal study with labafenogene marselecobac (SYNB-1934) for phenylketonuria, and will evaluate strategic options. Shares of the Cambridge, Mass.-based firm (NASDAQ:SYBX) fell 48.7%, or $1.68, to end Feb. 9 at $1.77. Synlogic will cease operations and reduce its workforce by more than 90%, retaining only certain employees to help with the wind-down.

Cambridge , Cambridgeshire , United-kingdom , Nasdaq , Synlogic-inc , Wall-street , Phenylketonuria , Synlogic-inc- , Labafenogene-marselecobac , Synb-1934 , Pku

FDA clears non-invasive Neuralace therapy for diabetic neuropathy

Neuralace Medical Inc. tied up a second U.S. FDA clearance for its Axon therapy, adding painful diabetic neuropathy (PDN) to the chronic nerve pain indication it received in 2021. An ‘electroceutical’ device, Axon employs non-invasive magnetic peripheral nerve stimulation (mPNS) to provide relief without leads, injections or implants.

Neuralace-medical-inc , Neuralace-medical , Bioworld-medtech , Regulatory , Endocrine-metabolic , Us- , Fda ,

From viral peptides, small-molecule drugs far beyond infection

Using interactions between viral peptides and human proteins as a starting point, researchers from Enyo Pharma Inc., the University of Lyon and other institutions were able to bootstrap themselves to a mitochondria-targeting small molecule that showed activity in a mouse model of nonalcoholic steatohepatitis (NASH) with chronic kidney disease.

Enyo-pharma-inc , University-of-lyon , Bioworld-science , Endocrine-metabolic , Nonalcoholic-steatohepatitis , Nash , Viral-host-interactions , Enyo-pharmaceuticals-inc- , Def3122 , Vinland , Drug-design

GLP-1 not all loss, sweet side emerges for med tech

Investors bailed on many med-tech companies last year, fearing that the frenzy surrounding GLP-1 agonists would tank companies in the weight-loss, diabetes and orthopedics segments. Their concerns now appear overblown in many instances, with some of the most directly affected businesses reporting a “rising tide” associated with an increased focus on obesity treatment that has lifted their boats rather than sinking them.

Bioworld-medtech , Zimmer-biomet-holdings-inc- , Stryker-corp- , Abbott-laboratories-inc- , Dexcom-inc- , Reshape-lifesciences-inc- , Insulet-corp- , Tandem-diabetes-care-inc- , Allurion-technologies-inc- , Glp-1 , Endocrine-metabolic

Caremt ha entregado más de 10 mil frascos de insulina durante primer trimestre del año

Caremt ha entregado más de 10 mil frascos de insulina durante primer trimestre del año
vtv.gob.ve - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vtv.gob.ve Daily Mail and Mail on Sunday newspapers.

Sweden , La-fria , Zulia , Venezuela , San-cristobal , Méco , Mexico , El-pinal , Carabobo , Suede , Sanitarium